Loading this company
Halozyme Therapeutics, Inc.
HALOPrices in USD
TickerWorth ScoreB61/100
What we think
Priced within our range of $91.61 to $153.99.
Price
$122.62USD up +$0.77 (+0.64%)
Quoted · Prices are delayed.
Showing the last price we hold for this listing, recorded 2026-10-19 15:49 UTC (6 hours ago).
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 2 models, on today’s numbers
$91.61–$153.99
What the price needs: revenue growth of 21.1%/yr for 5 years (our model assumes 16.6%).
Led by discounted cash flow (DCF) · Steady cash-flow business
Price $122.62Priced · Prices are delayed.
Is it a good business?
- Valuation33 out of 100
- Growth100 out of 100
- Financial health33 out of 100
- Past performance100 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$108.78 across 9 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 423 people.
Key stats
52-week range$61.23–$123.51
- Open
- $121.72
- Day high
- $123.51
- Day low
- $121.69
- Previous close
- $121.84
- Volume
- 396,297 · 0.18× avg
- Average volume
- 2,238,882
- Market cap
- $13,916,557,312.00
- P/E (TTM)
- 35.85
- Earnings per share
- $3.42
- Beta
- 0.88
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Changed leadership or its board
- Signed a material agreement
- Disclosed another material event
- Disclosed another material event
- Changed leadership or its board
- Reported quarterly or annual results
- Changed leadership or its board
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Torley HelenOption exercise · $368,200.00
- Torley HelenOpen-market sale ·
Not investment advice. TickerWorth Score is a model output.